Repligen Corp. (RGEN)
156.90
-4.76
(-2.94%)
USD |
NASDAQ |
Dec 12, 15:36
Repligen Research and Development Expense (Quarterly): 14.18M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Enovis Corp. | 29.74M |
| Teleflex, Inc. | 57.23M |
| Globus Medical, Inc. | 38.07M |
| Perspective Therapeutics, Inc. | 19.56M |
| Xtant Medical Holdings, Inc. | 0.634M |